Stay updated with breaking news from Ichnos Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ichnos Sciences and Almirall Enter into a Licensing Agreement for First-in-Class IL-1RAP Antagonist Monoclonal Antibody · Almirall is Granted Exclusive Global Rights to Develop and Commercialize ISB 880 for Use in Autoimmune Diseases NEW YORK, US...
/PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, and Almirall S.A....
Press release content from PR Newswire. The AP news staff was not involved in its creation.
/PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, and Almirall S.A....
Almirall is granted exclusive global rights to develop and commercialise ISB 880 for use in autoimmune diseases